OBJECTIVES: A pilot project concerning the evaluation of potential cost-saving for switching from chemotherapy (rituximab) intravenous injection (IV) to chemotherapy subcutaneous injection (SC) at national level in France” was selected to demonstrate added benefits beyond clinical effectiveness.   METHODS: To define the added value of rituximab SC injection improvement a 5-step methodology was defined as follow: 1) Define the key value drivers (cost/benefits), 2) Implement decision tree, 3) Estimate the associated patient flow, 4) Evaluate the direct and indirect costs of patient flow including hospital and insurance perspectives, 5) Communication to the stakeholders. For rituximab SC injection versus rituximab IV injection the decision tree model was developed using the French health care with rituximab marketing authorizations. Epidemiologic data were estimated with internal market share data and the French health watch institute. RESULTS: Four main benefits emerged at national level; (i) A reduction in staff time was observed for nurses, pharmacists and technicians leading to a potential saving at 300 000€ per year. (ii) A potential saving of 500 000€ per year was observed for the reduction in consumables. (iii) The shorter occupancy of chair for SC injection was leaded to a potential saving of 700 000€ per year. (iv) Reduction in wastage was 300 000€ per year thanks to sub-cutaneous injection.   CONCLUSIONS: Results showed that cost-saving from switching for IV to SC exist. Other potential benefits should be investigated to demonstrate all value of medicine product. Therefore, a quality of life study is planned to demonstrate potential added value of rituximab SC vs. rituximab IV in France. Cost-effectiveness study should be also performed to demonstrate potential cost saving per quality adjusted life year.